- Home
- MODD vs ANTX Comparison
MODD vs ANTX Comparison
Compare MODD & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ANTX
- Stock Information
- Founded
- MODD 1998
- ANTX 2017
- Country
- MODD United States
- ANTX United States
- Employees
- MODD N/A
- ANTX N/A
- Industry
- MODD Industrial Specialties
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- ANTX Health Care
- Exchange
- MODD Nasdaq
- ANTX Nasdaq
- Market Cap
- MODD 33.0M
- ANTX 34.4M
- IPO Year
- MODD N/A
- ANTX 2022
- Fundamental
- Price
- MODD $0.49
- ANTX $1.23
- Analyst Decision
- MODD
- ANTX Buy
- Analyst Count
- MODD 0
- ANTX 2
- Target Price
- MODD N/A
- ANTX $2.00
- AVG Volume (30 Days)
- MODD 260.9K
- ANTX 64.6K
- Earning Date
- MODD 11-14-2025
- ANTX 11-12-2025
- Dividend Yield
- MODD N/A
- ANTX N/A
- EPS Growth
- MODD N/A
- ANTX N/A
- EPS
- MODD N/A
- ANTX N/A
- Revenue
- MODD N/A
- ANTX N/A
- Revenue This Year
- MODD N/A
- ANTX N/A
- Revenue Next Year
- MODD N/A
- ANTX N/A
- P/E Ratio
- MODD N/A
- ANTX N/A
- Revenue Growth
- MODD N/A
- ANTX N/A
- 52 Week Low
- MODD $0.49
- ANTX $0.98
- 52 Week High
- MODD $2.37
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- MODD 21.81
- ANTX 48.89
- Support Level
- MODD $0.68
- ANTX $1.14
- Resistance Level
- MODD $0.60
- ANTX $1.36
- Average True Range (ATR)
- MODD 0.04
- ANTX 0.07
- MACD
- MODD -0.01
- ANTX 0.00
- Stochastic Oscillator
- MODD 3.62
- ANTX 43.48
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.